US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

In-vivo lung fibrosis staging in a bleomycin-mouse model: a new

HELIOS Monoclonal Antibody (22F6), Brilliant Ultra Violet™ 563

Frontiers Novel Anti-fibrotic Therapies

University of pennsylvaniaPatents

A small molecule inhibitor of the UBE2F-CRL5 axis induces

The mechanism of how CD95/Fas activates the Type I IFN/STAT1 axis

Progress in drug delivery system for fibrosis therapy - ScienceDirect

media.springer/full/springer-static/imag

CD45 Antibody, anti-mouse, REAfinity™

Antibody-drug conjugates targeting CD248 inhibits liver fibrosis

CD5L is a pleiotropic player in liver fibrosis controlling damage

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a

PHD1 regulates p53‐mediated colorectal cancer chemoresistance